How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
Beam Therapeutics' fair value estimate has shifted from US$49.93 to US$50.27, a small but telling adjustment in how its equity story is being framed. This change sits against a backdrop of research coverage that highlights higher price targets, new liver focused programs, regulatory updates, and fresh non dilutive financing, with analysts balancing optimism on the pipeline against execution and sector risk. As you read on, you will see how to track these moving pieces and keep up with the evolving analyst narrative around Beam. Stay updated as the Fair Value for Beam Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Beam Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Several firms, including Wedbush, Canaccord, BofA and RBC Capital, have lifted their price targets on Beam Therapeutics, signaling higher conviction in the company's valuation relative to prior views. Canac
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics (BEAM) had its price target raised by Citigroup Inc. from $64.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentGlobeNewswire
- RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.MarketBeat
- Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
BEAM
Earnings
- 2/24/26 - Beat
BEAM
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/5/26 - Form 8-K
- 2/26/26 - Form 4
- BEAM's page on the SEC website